Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical Prostatectomy

Journal of Urology

Volumn 179, Issue 5 SUPPL., 2008, Pages

  Moul, Judd W ^a,b   Wu, Hongyu ^a   Sun, Leon ^a   McLeod, David G ^b   Amling, Christopher ^d   Donahue, Timothy ^b   Kusuda, Leo ^e   Sexton, Wade ^f   O'Reilly, Keith ^h   Hernandez, Javier ^g   Chung, Andrew ^c   Soderdahl, Douglas ⁱ  

^a Uniformed Services University of the Health Sciences   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c Andrews AFB ^*  (United States)

^d NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^e NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^f WILFORD HALL MEDICAL CENTER   (United States)

^g BROOKE ARMY MEDICAL CENTER   (United States)

^h MADIGAN ARMY MEDICAL CENTER   (United States)

ⁱ EISENHOWER ARMY MEDICAL CENTER   (United States)

Author keywords

hormones; prostate specific antigen; prostatectomy; prostatic neoplasms; recurrence

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA BASE; EARLY INTERVENTION; FOLLOW UP; GLEASON SCORE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; ORCHIECTOMY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; THERAPY DELAY; UNIVARIATE ANALYSIS;

EID: 41849105088     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.03.138     Document Type: Article

References (20)

1. A. Jemal T. Murray A. Samuels A. Ghafoor E. Ward M.J. Thun Cancer statistics, 2003 CA Cancer J Clin 53 2003 5
2. J.W. Moul Treatment options for prostate cancer: part I-stage, grade, PSA, and changes in the 1990’s Am J Manag Care 4 1998 1031
3. J.W. Moul H. Wu L. Sun D.G. McLeod C. Armling R. Lance Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database Surgery 132 2002 213
4. J.W. Moul Prostate specific antigen only progression of prostate cancer J Urol 163 2000 1632
5. B. Djavan J.W. Moul A. Zlotta M. Remzi V. Ravery PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millenium Eur Urol 43 2003 12
6. M.S. Katz M.J. Zelefsky E.S. Venkatraman Z. Fuks A. Hummer S.A. Leibel Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer J Clin Oncol 21 2003 483
7. C.R. Pound A.W. Partin M.A. Eisenberger D.W. Chan J.D. Pearson P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591
8. L. Sun K. Gancarczyk D.G. McLeod C. Kane L. Kusuda R. Lance Introduction to department of defense Center for Prostate Disease Research (CPDR) multicenter national prostate cancer database with 242,227 records on 11,637 men, and analysis of changes in the PSA-era Urol Oncol 6 2001 203
9. H.B. Carter J.I. Epstein D.W. Chan J.L. Fozard J.D. Pearson Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer JAMA 277 1997 1456
10. C.L. Amling E.J. Bergstralh M.L. Blute J.M. Slezak H. Zincke Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165 2001 1146
11. S.J. Freedland W.J. Aronson G.S. Csathy C.J. Kane C.L. Amling J.C. Presti Jr. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database Urology 61 2003 742
12. A.V. D’Amico Combined-modality staging for localized adenocarcinoma of the prostate Oncology 15 2001 1049
13. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial The Medical Research Council Prostate Cancer Working Party Investigators Group Br J Urol 79 1997 235
14. M. Bolla L. Collette L. Blank P. Warde J.B. Dubois R.O. Mirimanott Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial Lancet 360 2002 103
15. D. Kirk Immediate vs. delayed hormone treatment for prostate cancer: how safe is androgen deprivation? BJU Int 86 suppl. 2000 220
16. E.M. Messing J. Monola M. Sarsody G. Wilding E.D. Crawford D. Trump Immediate hormonal therapy compared with observation following radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781
17. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials Prostate Cancer Trialists’ Collaborative Group Lancet 355 2000 1491
18. A. Hurtado-Coll S.L. Goldenberg M.E. Gleave L. Klotz Intermittent androgen suppression in prostate cancer: the Canadian experience Urology 60 2002 52
19. W.A. See M.P. Wirth D.G. McLeod P. Iversen I. Klimberg D. Gleason Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program J Urol 168 2002 429
20. N.E. Fleshner J. Trachtenberg Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects J Urol 154 1995 1642